UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells

Metallomics, 2018-03, Vol.10 (3), p.414-425

2018

Volltextzugriff (PDF)

Rational design and diversity-oriented synthesis of peptoid-based selective HDAC6 inhibitors

Chemical communications (Cambridge, England), 2016-01, Vol.52 (15), p.3219-3222

2016

Volltextzugriff (PDF)

Stability of murine bradykinin type 2 receptor despite treatment with NO, bradykinin, icatibant, or C1‐INH

Allergy (Copenhagen), 2015-03, Vol.70 (3), p.285-294

2015

Volltextzugriff (PDF)

In vitro and mouse in vivo characterization of the potent free fatty acid 1 receptor agonist TUG-469

Naunyn-Schmiedeberg's archives of pharmacology, 2013-12, Vol.386 (12), p.1021-1030

2013

Volltextzugriff (PDF)

Structure-activity relationships of suramin and pyridoxal-5'-phosphate derivatives as P2 receptor antagonists

Current pharmaceutical design, 2002-12, Vol.8 (26), p.2371-2399

2002

Volltextzugriff (PDF)

Profiling at recombinant homomeric and heteromeric rat P2X receptors identifies the suramin analogue NF449 as a highly potent P2X receptor antagonist

Neuropharmacology, 2005-03, Vol.48 (3), p.461-468

2005

Volltextzugriff (PDF)

Suramin Derivatives as Inhibitors and Activators of Protein-tyrosine Phosphatases

The Journal of biological chemistry, 2004-04, Vol.279 (15), p.14713-14725

2004

Volltextzugriff (PDF)

Expression profile of copper transporters in sensitive and cisplatin/oxaliplatin-resistant tumor cell lines

International journal of clinical pharmacology and therapeutics, 2005-12, Vol.43 (12), p.597-598

2005

Volltextzugriff (PDF)

Identification of new genes involved in cisplatin resistance and their expression profile in 18 human tumor cell lines

International journal of clinical pharmacology and therapeutics, 2005-12, Vol.43 (12), p.579-580

2005

Volltextzugriff (PDF)

Novel modulators to overcome P-glycoprotein-mediated multidrug resistance in tumor cells

International journal of clinical pharmacology and therapeutics, 2004-11, Vol.42 (11), p.644-645

2004

Volltextzugriff (PDF)

Rational design and diversity-oriented synthesis of peptoid-based selective HDAC6 inhibitorsElectronic supplementary information (ESI) available: Experimental details (synthetic protocols, bioassays, X-ray crystallography, computational methods), characterization data of new compounds, and copies of NMR spectra. CCDC 1434499. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c5cc10301k

2016-02

Volltextzugriff (PDF)

Comparison of the usefulness of the MTT, ATP, and calcein assays to predict the potency of cytotoxic agents in various human cancer cell lines

Journal of biomolecular screening, 2004-09, Vol.9 (6), p.506-515

2004

Volltextzugriff (PDF)

Differential gene expression studies in cisplatin-sensitive versus cisplatin-resistant human cancer cell lines

International journal of clinical pharmacology and therapeutics, 2004-11, Vol.42 (11), p.637-639

2004

Volltextzugriff (PDF)

Stability of murine bradykinin type 2 receptor despite treatment with NO , bradykinin, icatibant, or C 1‐ INH

Allergy (Copenhagen), 2015-03, Vol.70 (3), p.285-294

2015

Volltextzugriff (PDF)

Molecular determinants of potent P2X2 antagonism identified by functional analysis, mutagenesis, and homology docking

Molecular pharmacology, 2011-04, Vol.79 (4), p.649-661

2011

Volltextzugriff (PDF)

Salt bridge switching from Arg290/Glu167 to Arg290/ATP promotes the closed-to-open transition of the P2X2 receptor

Molecular pharmacology, 2013-01, Vol.83 (1), p.73-84

2013

Volltextzugriff (PDF)

G-protein coupled receptor kinases and their inhibitors

Expert opinion on therapeutic patents, 2000-06, Vol.10 (6), p.917-928

Kassack, Matthias U

2000

Volltextzugriff (PDF)

Inhibition of platelet functions and thrombosis through selective or nonselective inhibition of the platelet P2 receptors with increasing doses of NF449 [4,4',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis-(carbonylimino)))tetrakis-benzene-1,3-disulfonic acid octasodium salt]

The Journal of pharmacology and experimental therapeutics, 2005-07, Vol.314 (1), p.232-243

2005

Volltextzugriff (PDF)

Sila-haloperidol: A Silicon Analogue of the Dopamine (D2) Receptor Antagonist Haloperidol

Organometallics, 2004-09, Vol.23 (19), p.4468-4477

2004

Volltextzugriff (PDF)

The suramin analog 4,4',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis (carbonylimino)))tetra-kis-benzenesulfonic acid (NF110) potently blocks P2X3 receptors: subtype selectivity is determined by location of sulfonic acid groups

Molecular pharmacology, 2006-06, Vol.69 (6), p.2058-2067

2006

Volltextzugriff (PDF)

Dopamine/Serotonin Receptor Ligands. 10: SAR Studies on Azecine-type Dopamine Receptor Ligands by Functional Screening at Human Cloned D 1 , D 2L , and D 5 Receptors with a Microplate Reader Based Calcium Assay Lead to a Novel Potent D 1 /D 5 Selective Antagonist

Journal of medicinal chemistry, 2006-01, Vol.49 (2), p.760-769

2006

Volltextzugriff (PDF)

Structure−Activity Study of Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist TUG-469

ACS medicinal chemistry letters, 2010-10, Vol.1 (7), p.345-349

2010

Volltextzugriff (PDF)

Charged bipolar suramin derivatives induce aggregation of the prion protein at the cell surface and inhibit PrPSc replication

Journal of cell science, 2005-11, Vol.118 (Pt 21), p.4959-4973

2005

Volltextzugriff (PDF)

Bis(1H-2-indolyl)methanones as a Novel Class of Inhibitors of the Platelet-Derived Growth Factor Receptor Kinase

Journal of medicinal chemistry, 2002-02, Vol.45 (5), p.1002-1018

2002

Volltextzugriff (PDF)

Use‐dependent inhibition of the skeletal muscle ryanodine receptor by the suramin analogue NF676

British journal of pharmacology, 2005-10, Vol.146 (4), p.525-533

2005

Volltextzugriff (PDF)

1 – 25 von 63

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(60)
Mit Volltextzugriff
(48)

Publikationsform

Artikel
(62)
Reviews
(1)

Sprache

Englisch
(61)

Erscheinungsjahr

n.n

Thema

Science & Technology
(40)
Life Sciences & Biomedicine
(36)
Humans
(28)
Pharmacology & Pharmacy
(22)
Animals
(15)
Cell Line, Tumor
(12)
Chemistry
(11)
Chemistry, Medicinal
(11)
Physical Sciences
(11)
Biological And Medical Sciences
(10)
Female
(10)
Medical Sciences
(10)
Biochemistry & Molecular Biology
(8)
Calcium - Metabolism
(8)
Pharmacology. Drug Treatments
(8)
Structure-Activity Relationship
(8)
Antineoplastic Agents - Pharmacology
(7)
Cisplatin - Pharmacology
(6)
Cytotoxicity
(6)
Suramin - Analogs & Derivatives
(6)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells

Rational design and diversity-oriented synthesis of peptoid-based selective HDAC6 inhibitors

Stability of murine bradykinin type 2 receptor despite treatment with NO, bradykinin, icatibant, or C1‐INH

In vitro and mouse in vivo characterization of the potent free fatty acid 1 receptor agonist TUG-469

Structure-activity relationships of suramin and pyridoxal-5'-phosphate derivatives as P2 receptor antagonists

Profiling at recombinant homomeric and heteromeric rat P2X receptors identifies the suramin analogue NF449 as a highly potent P2X receptor antagonist

Suramin Derivatives as Inhibitors and Activators of Protein-tyrosine Phosphatases

Expression profile of copper transporters in sensitive and cisplatin/oxaliplatin-resistant tumor cell lines

Identification of new genes involved in cisplatin resistance and their expression profile in 18 human tumor cell lines

Novel modulators to overcome P-glycoprotein-mediated multidrug resistance in tumor cells

Comparison of the usefulness of the MTT, ATP, and calcein assays to predict the potency of cytotoxic agents in various human cancer cell lines

Differential gene expression studies in cisplatin-sensitive versus cisplatin-resistant human cancer cell lines

Stability of murine bradykinin type 2 receptor despite treatment with NO , bradykinin, icatibant, or C 1‐ INH

Molecular determinants of potent P2X2 antagonism identified by functional analysis, mutagenesis, and homology docking

Salt bridge switching from Arg290/Glu167 to Arg290/ATP promotes the closed-to-open transition of the P2X2 receptor

G-protein coupled receptor kinases and their inhibitors

Inhibition of platelet functions and thrombosis through selective or nonselective inhibition of the platelet P2 receptors with increasing doses of NF449 [4,4',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis-(carbonylimino)))tetrakis-benzene-1,3-disulfonic acid octasodium salt]

Sila-haloperidol: A Silicon Analogue of the Dopamine (D2) Receptor Antagonist Haloperidol

The suramin analog 4,4',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis (carbonylimino)))tetra-kis-benzenesulfonic acid (NF110) potently blocks P2X3 receptors: subtype selectivity is determined by location of sulfonic acid groups

Dopamine/Serotonin Receptor Ligands. 10: SAR Studies on Azecine-type Dopamine Receptor Ligands by Functional Screening at Human Cloned D 1 , D 2L , and D 5 Receptors with a Microplate Reader Based Calcium Assay Lead to a Novel Potent D 1 /D 5 Selective Antagonist

Structure−Activity Study of Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist TUG-469

Charged bipolar suramin derivatives induce aggregation of the prion protein at the cell surface and inhibit PrPSc replication

Bis(1H-2-indolyl)methanones as a Novel Class of Inhibitors of the Platelet-Derived Growth Factor Receptor Kinase

Use‐dependent inhibition of the skeletal muscle ryanodine receptor by the suramin analogue NF676

Suchergebnisse filtern